Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glucose Metabolism Disorders (Including Diabetes Mellitus) Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Glucose Variability and Cognition in Prediabetes

NCT04201600
View directory record Official record
Conditions
Glucose Metabolism Disorders (Including Diabetes Mellitus), Cognitive Decline, Functional Status, PreDiabetes, Aging, Depression
Interventions
Continuous Glucose Monitoring System (CGMS)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 21, 2026, 9:42 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

NCT00958269
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
dutogliptin, placebo, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Tempe, Arizona • Long Beach, California • Lynwood, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

NCT00800683
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 1356, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
24
States / cities
Phoenix, Arizona • Chula Vista, California • Riverside, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Integrating Cultural Aspects Into Diabetes Education

NCT05492916
View directory record Official record
Conditions
PreDiabetes
Interventions
Diabetes Prevention Program (DPP), Community-Supported Agriculture (CSA)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Accessible and Inclusive Diabetes Telecoaching Self-Management Program

NCT04927377
View directory record Official record
Conditions
Diabete Type 2, Disability Physical
Interventions
AI4DM, Attention-control
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

NCT00328172
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily, Metformin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
21 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
34
States / cities
Chula Vista, California • La Jolla, California • Walnut Creek, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes

NCT04791787
View directory record Official record
Conditions
Glucose Metabolism Disorders (Including Diabetes Mellitus), Energy Supply; Deficiency, Type 2 Diabetes
Interventions
Standard weight maintaining diet, Weight maintaining isocaloric ketogenic diet, Beta-hydroxy butyrate
Other · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial

NCT03675360
View directory record Official record
Conditions
Diabetes, PreDiabetes, Metabolic Disease, Hyperglycemia, Diet Modification, Glucose Intolerance, Glucose Metabolism Disorders (Including Diabetes Mellitus), Endocrine System Diseases
Interventions
Low-Carbohydrate Diet
Behavioral
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
40 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jul 21, 2026, 9:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

NCT06575426
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Severe Hypoglycemia, Xenotransplantation, Hypoglycemic Episode, Islet Transplantation in Diabetes Mellitus Type 1, Glucose Metabolism Disorders (Including Diabetes Mellitus), Immune System Diseases, Autoimmune Diseases, Metabolic Disease
Interventions
OPF-310
Combination Product
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 9:42 AM EDT
Terminated Phase 4 Interventional

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

NCT04938388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Semaglutide Pill, Fresh organic vegetables
Drug · Dietary Supplement
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

NCT02320721
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
64
States / cities
Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Almond Consumption and Glycemia

NCT03236116
View directory record Official record
Conditions
Glucose Intolerance, Appetite Disorders, Glucose Metabolism Disorders (Including Diabetes Mellitus), Lipid Metabolism Disorder
Interventions
Almonds, Control (no nuts)
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
3
States / cities
Indianapolis, Indiana • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

NCT01334151
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Insulin LISPRO, recombinant human insulin
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Kombucha on Blood Sugar Levels in Humans

NCT04051294
View directory record Official record
Conditions
Glucose, Glucose Metabolism Disorders (Including Diabetes Mellitus), Blood Sugar; High
Interventions
Commercial kombucha tea, Brewed kombucha tea, Control: Tea, Control: Water
Dietary Supplement · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
30 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jul 21, 2026, 9:42 AM EDT
Recruiting No phase listed Observational

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

NCT06278207
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (BAY 94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)

NCT00015626
View directory record Official record
Conditions
Insulin Resistance, Diabetes Mellitus
Interventions
Metformin, skin biopsy, diet and exercise, pioglitazone, rosiglitazone
Drug · Procedure · Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:42 AM EDT
Completed No phase listed Observational Results available

Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns

NCT02138097
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
615,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Jul 21, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

NCT03566511
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Diazoxide, Placebo
Drug
Lead sponsor
Meredith Hawkins
Other
Eligibility
21 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Jul 21, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

NCT04029480
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to ertugliflozin 15 mg, Placebo to ertugliflozin 5 mg, Insulin, Metformin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 21, 2026, 9:42 AM EDT
Recruiting Not applicable Interventional

Culturally Tailored Program for Food-Insecure Adults: SPICE-D

NCT07361341
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2D)
Interventions
Food Bundle Intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 21, 2026, 9:42 AM EDT
Not yet recruiting Not applicable Interventional

Continuous Glucose Monitoring in Patients Undergoing Cardiopulmonary Bypass

NCT06861881
View directory record Official record
Conditions
Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Dexcom G7 Continuous Glucose Monitor
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 9:42 AM EDT
Active, not recruiting Not applicable Interventional

Development of an Inclusive Adaptive Treatment Strategy for Weight Loss in People With Prediabetes Using a Sequential Multiple Assignment Randomized Trial

NCT06976307
View directory record Official record
Conditions
Disabilities, Obesity and Overweight, Prediabetes
Interventions
High Carbohydrate Diet, Reduced Carbohydrate Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 9:42 AM EDT
Recruiting No phase listed Observational

Capability Assessment for Diet and Activity (CADA) Model for Diabetes

NCT06631105
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 21, 2026, 9:42 AM EDT
Completed No phase listed Observational

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

NCT05703880
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY948862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
15,948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Jul 21, 2026, 9:42 AM EDT